Literature DB >> 7666009

Biliary haptoglobin, a potent promoter of cholesterol crystallization at physiological concentrations.

G Yamashita1, S Ginanni Corradini, R Secknus, A Takabayashi, C Williams, L Hays, A L Chernosky, R T Holzbach.   

Abstract

BACKGROUND/AIMS: Several proteins present in human bile have been reported to promote cholesterol crystallization and thus are potentially important in the formation of cholesterol crystals as the initial stage in gallstone pathogenesis. To be physiologically relevant, such proteins must either be present in high concentration in bile or have a potent promoting activity. The current study explored several of the more abundant but unexamined biliary proteins based upon their also having sufficiently high serum concentrations that antibodies were available for both their isolation and quantitation.
METHODS: Protein purification was accomplished by immunoaffinity chromatography of bile followed by delipidation. Con A affinity chromatography of bile was used to obtain the bound fraction, a portion of which was delipidated. Crystallization-promoting activity of both the purified proteins and Con A-bound glycoprotein fractions (CABG) was measured by a photometric crystal growth assay. A competitive antibody-capture ELISA assay was developed to measure concentrations of alpha 1-antitrypsin, transferrin, and haptoglobin in native bile.
RESULTS: At their relevant physiological concentrations, biliary haptoglobin (15 micrograms/ml) had a crystallization-promoting activity twice that of the biliary IgM (75 micrograms/ml) used as a reference standard (P < 0.05). Biliary transferrin (20 micrograms/ml) had only modest promoting activity (P < 0.05). Biliary alpha 1-antitrypsin (50 micrograms/ml), by contrast, showed no promoting activity. Delipidation of the CABG fraction decreased its promoting activity by 75%. Biliary haptoglobin accounts for about 30% of delipidated total CABG-promoting activity.
CONCLUSIONS: Biliary haptoglobin at its physiological concentration has a highly potent crystallization-promoting activity and thus becomes a candidate for major attention in understanding gallstone pathogenesis.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7666009

Source DB:  PubMed          Journal:  J Lipid Res        ISSN: 0022-2275            Impact factor:   5.922


  7 in total

1.  Gallbladder dysfunction enhances physical density but not biochemical metastability of biliary vesicles.

Authors:  Y Sunami; S Tazuma; G Kajiyama
Journal:  Dig Dis Sci       Date:  2000-12       Impact factor: 3.199

Review 2.  Cholesterol crystallisation in bile.

Authors:  P Portincasa; K J van Erpecum; G P Vanberge-Henegouwen
Journal:  Gut       Date:  1997-08       Impact factor: 23.059

3.  Quantitative assessment of comparative potencies of cholesterol-crystal-promoting factors: relation to mechanistic characterization.

Authors:  T Nishioka; S Tazuma; G Yamashita; G Kajiyama
Journal:  Biochem J       Date:  1998-06-01       Impact factor: 3.857

4.  Partial replacement of bile salts causes marked changes of cholesterol crystallization in supersaturated model bile systems.

Authors:  T Nishioka; S Tazuma; G Yamashita; G Kajiyama
Journal:  Biochem J       Date:  1999-06-01       Impact factor: 3.857

5.  Role of phospholipase A2 in cholesterol gallstone formation is associated with biliary phospholipid species selection at the site of hepatic excretion: indirect evidence.

Authors:  Y Hattori; S Tazuma; G Yamashita; H Ochi; Y Sunami; T Nishioka; H Hyogo; S Yasumiba; T Kajihara; K Nakai; K Tsuboi; Y Asamoto; M Sakomoto; G Kajiyama
Journal:  Dig Dis Sci       Date:  2000-07       Impact factor: 3.199

Review 6.  The pathogenesis of cholesterol gallstones a review.

Authors:  S M Strasberg
Journal:  J Gastrointest Surg       Date:  1998 Mar-Apr       Impact factor: 3.267

7.  Comparative proteomic analysis of gallbladder bile proteins related to cholesterol gallstones.

Authors:  Diancai Zhang; Jianbin Xiang; Liying Wang; Zhibin Xu; Lidong Sun; Feng Zhou; Xiliang Zha; Duan Cai
Journal:  PLoS One       Date:  2013-01-17       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.